

GROUP TERM LIFE



U.S. Group Term Life Market Survey

Summary of 2022 Results

CONTENTS

Participating Companies		
Background	4	
Summary Results	5-8	
Group Term Life and AD&D In-force Results	5	
Group Term Life and AD&D Sales Results	6	
Group Term Life Growth – Cases and Lives	7	
Group Term Life Pricing and Volume Levels	8	

General Re Life Corporation is committed to adhering to antitrust laws, and cautions all recipients that this report is intended solely to provide general industry knowledge. Under no circumstances shall it be used as a means for representatives of competing companies, and/or firms, to reach any understanding whatsoever, whether it be about specific pricing of specific products, if particular products should be marketed to the public, or the terms under which products are marketed.

PARTICIPATING COMPANIES

- Aflac
- Dearborn Group
- Elevance Health (formerly Anthem, Inc.)
- Equitable
- Guardian Life
- The Hartford
- Kansas City Life
- Lincoln Financial Group
- MetLife
- Mutual of America
- Mutual of Omaha
- New York Life Group Benefit Solutions
- OneAmerica
- Principal Financial Group


- Prudential
- Renaissance Life & Health
- Securian Financial Group
- The Standard
- Sun Life Financial
- Symetra
- Transamerica
- Union Labor Life
- UnitedHealthcare Specialty Benefits
- Unum
- USAble Life
- US Alliance Life & Security Company
- Voya Employee Benefits

BACKGROUND

Gen Re is pleased to present the results of our 2022 U.S. Group Term Life Market Survey. This annual survey covers the Group Term Life (GTL) and Accidental Death and Dismemberment (AD&D) industry, tracking sales and in-force results as well as lapse rate and employee-paid data. The Market Survey continues to provide a valuable opportunity for participants to benchmark their results against those of their peers, as well as the industry as a whole. Of the 27 companies participating this year, 20 have been long-time contributors in the Market Survey, providing data over the past 10 survey years.


Group Term Life and AD&D In-force Results

Twenty-seven companies provided GTL results for 2022. Twenty-five provided AD&D results. On a combined basis, total GTL and AD&D in-force premium reached \$32.8 billion, with GTL representing the majority (94%) of the total. (Exhibit A)




GTL in-force premium growth remained positive in 2022. After reaching a 10-year peak in 2021, GTL growth rates slowed from 6% to 4%.

AD&D in-force premium has been steadily growing since seeing a five-year market low in 2020. In 2022, premium rose by 5%. (Exhibit B)



Group Term Life and AD&D Sales Results


Participating companies reported over \$3.2 billion in combined GTL and AD&D sales premium in 2022, with GTL accounting for 92% of the total. (Exhibit C)



GTL new sales premium continues to show strong growth, increasing 7% for the second year after a large decline in 2020.

The top 10 companies held 84% of the market share for new sales premium, contributing approximately \$2.5B of total 2022 sales.


AD&D sales premium growth had a slight increase of 2%. (Exhibit D)




Group Term Life Growth – Cases and Lives

GTL new sales case counts remained flat year-over-year. Only 37% of companies reporting this data (10 out of 27) experienced a positive result. Seven companies reported a decrease greater than 10%. In-force case counts were up by 2% in 2022. (Exhibit E)

For companies providing sales case size breakdown information for the two-year period, the 10–99 category accounted for the highest percentage of cases in 2022 (55%), followed by the 1–9 grouping (28%). Results were similar for in-force (51% and 30%, respectively). Less than 1% fell in the 5,000+ range for both sales and in-force.



After seeing moderate growth in 2021, new sales lives decreased by 5% in 2022. In-force lives grew by 4% year-over-year. (Exhibit F)



Group Term Life Pricing and Volume Levels

Average face amounts for new sales grew 11% in 2022. In-force average face amounts continue to average over \$100,000.

Monthly premium rates were up by 6% for new sales and remained flat for in-force. (Exhibit G)

Exhibit G. GTL Average Face Amount and Monthly Premium Rate ---

	Average Face Amount	Monthly Premium Rate (per 1,000)
In-force	\$102,817	\$0.198
Growth	1%	0%
New Sales	\$97,973	\$0.193
Growth	11%	6%

New sales face amounts averaged below \$100,000 for the first time since 2019.

Average premium per life grew for both new sales and in-force business. (Exhibit H)

Exhibit H. GTL Average Premium Per Life -----

		Percentage of Companies		
	Average Premium Per Life	Less than \$150	\$150 to \$250	\$250 or more
In-force Growth	\$241 1%	19%	62%	19%
New Sales Growth	\$209 13%	38%	41%	21%

A small number of companies strongly influenced the average premium per life for new sales result. Removing just two companies would result in a 5% increase vs. a 13% increase year-over-year.

ABOUT GEN RE

Gen Re, a Berkshire Hathaway Company, is one of the leading Life/Health and Property/Casualty reinsurers in the world. Our North American Life and Health reinsurance company, General Re Life Corporation, has superior financial strength ratings among Life and Health reinsurers.

A++ (Superior) AA+ Aa1

A.M. Best Standard & Poor's Moody's

Through our research, we offer valuable information and insights to our clients about their markets. We deliver customized reinsurance programs and risk management solutions for the following lines of business:



Accident



Critical Illness



Individual
Disability Income



Group Life and AD&D



Individual Life



Medicare Supplement

GEN RE RESEARCH CENTER

9 Donald B. Dean Drive South Portland, ME 04106 Tel. 207 347 4600

genre.com/research-center

The difference is...the quality of the promise.



genre.com | genre.com/perspective | Twitter: @Gen_Re

Gen Re has produced this comprehensive report for the exclusive use of the participating companies. No part may be shared with other organizations, redistributed, reproduced or reprinted in whole or in part without Gen Re's written permission. The information contained in this report has been gathered from participating companies. Gen Re takes great care to check and verify the data provided, but makes no representation as to the accuracy of information submitted by participating companies.

© 2022 General Re Life Corporation. No portion of this publication may be reproduced without permission.